Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

Core Insights - Can-Fite BioPharma Ltd. has completed patient enrollment in its Phase 2a clinical trial for Namodenoson, a drug targeting advanced pancreatic adenocarcinoma, with top-line efficacy data expected in Q3 2026 [1][3] Group 1: Clinical Trial Details - The Phase 2a study is a multicenter, open-label trial focusing on patients with advanced pancreatic adenocarcinoma who have progressed after at least one prior therapy [2] - The primary endpoint of the study is safety, with additional evaluations of clinical activity and pharmacokinetics of Namodenoson, administered at a dose of 25 mg twice daily in 28-day cycles [2] - Namodenoson has shown a favorable safety profile to date, with ongoing monitoring of participants [2][3] Group 2: Drug Profile and Designations - Namodenoson is a selective A3 adenosine receptor agonist that has demonstrated anti-tumor activity in preclinical models for pancreatic cancer and is also being tested for advanced liver cancer [3] - The drug has received Orphan Drug Designation from the U.S. FDA for the treatment of pancreatic cancer, indicating its potential significance in addressing unmet medical needs [4] Group 3: Company Overview - Can-Fite BioPharma is an advanced clinical-stage drug development company with a focus on multi-billion dollar markets in cancer, liver, and inflammatory diseases [5] - The company’s lead drug candidate, Piclidenoson, has recently reported topline results in a Phase 3 trial for psoriasis and is advancing in pivotal trials [5] - Can-Fite's pipeline includes Namodenoson, which is also in a Phase III trial for hepatocellular carcinoma and has shown potential for treating other cancers [5]